Cholinergic Neurotransmission: Synthesis, Hydrolysis, and Receptors
Acetylcholine (ACh; quaternary ammonium; most ancient neurotransmitter; ubiquitous: NMJ, autonomic ganglia, CNS basal forebrain/brainstem, parasympathetic postganglionic, enteric): synthesis: ChAT (choline acetyltransferase; EC 2.3.1.6; cytoplasmic; uses acetyl-CoA (mitochondrial export) + choline → ACh + CoA; Km choline ~0.5 mM; Km AcCoA ~0.1 mM; CHT1/SLC5A7 high-affinity choline transporter (neuronal membrane; Na+-dependent; rate-limiting substrate supply; dynamin-dependent endocytosis of used CHT1)); choline sources: dietary phosphatidylcholine/sphingomyelin → intestinal hydrolysis → choline; CDP-choline pathway re-synthesis; choline re-uptake post-AChE hydrolysis; storage: VAChT (vesicular ACh transporter; SLC18A3; H+-ATPase antiport; ACh → synaptic vesicle); exocytosis: AP180/SNAP-25/VAMP2/syntaxin-1 SNARE complex; Ca2+-triggered fusion; hydrolysis: AChE (acetylcholinesterase; EC 3.1.1.7; serine hydrolase; Ser203-His447-Glu334 catalytic triad; one of fastest enzymes (kcat ~10^4 s−1); synaptic cleft + erythrocyte + NMJ; AChE-S (synaptic/asymmetric; ColQ/PRiMA anchoring); AChE-G4 (globular tetramer; brain; Alzheimer's: AChE ↓)); BuChE (butyrylcholinesterase; BCHE; plasma/glia; broad substrate); organophosphates: irreversible Ser203 phosphorylation → AChE inhibition → cholinergic crisis; carbamates: reversible; donepezil/galantamine: reversible competitive AChE inhibitors (Alzheimer's therapy)); receptors: nicotinic (nAChR; ligand-gated ion channel (LGIC); pentamer; α/β/γ/δ/ε subunits; α7-homomeric (CHRNA7; low ACh affinity; high Ca2+ permeability; presynaptic; immune cells; α7 Cys-loop receptor; desensitisation rapid; bungarotoxin-sensitive); α4β2 (CNS; nicotine addiction target); NMJ α1β1γ/εδ (muscle)); muscarinic (mAChR; M1–M5 GPCR; M1/M3/M5: Gq/11 → PLCbeta → IP3/DAG → Ca2+/PKC; M2/M4: Gi → AC ↓ → cAMP ↓ + GIRK K+ channels; atropine competitive antagonist); cholinergic anti-inflammatory (vagus → CAP (cholinergic anti-inflammatory pathway); efferent vagus → splenic nerve → catecholamine → splenic α7nAChR T cells → α7 → JAK2 → STAT3 → cholinergic anti-inflammatory reflex → TNF-α ↓).
Spirulina Mechanisms in Cholinergic Signalling
Choline Provision and ChAT Substrate Support
Choline (essential nutrient; de novo synthesis limited (PEMT liver; PE→PC; requires SAM×3); primarily dietary; AI 550 mg/day (male)/425 mg/day (female); CHT1-mediated neuronal uptake rate-limiting for ACh synthesis): spirulina choline content (~60–100 mg/100g; primarily lecithin/phosphatidylcholine form; at 10g/day: ~6–10 mg choline; modest contribution; lower than egg yolk (130 mg/egg) but meaningful in low-choline diets); spirulina supports ChAT substrate: (1) choline provision → CHT1 substrate → cholinergic neuron ACh synthesis +5–10% (cholinergically challenged/low-choline background); (2) acetyl-CoA: spirulina AMPK → pyruvate dehydrogenase (PDH) → acetyl-CoA ↑ (mitochondrial) → cytoplasmic export via ACLY → ChAT substrate; (3) B5 (pantothenate; CoA precursor; spirulina ~3.5 mg/100g B5 → at 10g: ~350 μg; CoA → acetyl-CoA availability for ChAT); (4) Nrf2 → ChAT Cys protection (ChAT Cys residues oxidatively inactivated; Nrf2 → TRX/GSH → ChAT Cys-SH maintained → ACh synthesis preserved under oxidative neuroinflammation).
α7-nAChR Anti-Inflammatory Potentiation
α7-nAChR (CHRNA7; α-7 homotrimeric (actually pentameric); Ca2+-permeable; expressed: brain (hippocampus/prefrontal cortex/basal forebrain cholinergic neurons); macrophage/microglia/dendritic cells/T cells (immune α7 anti-inflammatory); α7 signalling in macrophage: ACh/nicotine/GTS-21 → α7 → JAK2 Tyr1007 → STAT3 Tyr705 (non-canonical; Ca2+-independent; direct α7-JAK2 interaction) → STAT3 nuclear → anti-inflammatory targets (SOCS3 ↑; NF-κB ↓; IL-10 ↑); also α7 → PI3K/Akt → NF-κB IκBα stabilisation; α7 agonists (GTS-21/DMXBA; PNU-282987; choline at mM; nicotine) → TNF-α ↓ 30–50% in LPS macrophage): spirulina potentiates α7-nAChR anti-inflammatory: (1) phycocyanin → downstream NF-κB ↓ convergent with α7-STAT3 anti-inflammatory (parallel NF-κB inhibition; additive −20–35% TNF-α vs α7 activation alone); (2) AMPK → α7 expression (AMPK → ChAT/VAChT transcription ↑ → synaptic ACh ↑ → α7 stimulation ↑); (3) vagal tone: spirulina → NO → cardiac vagal tone ↑ (HR variability ↑) → more efferent vagal ACh → α7 splenic T cell → anti-inflammatory reflex strengthened; (4) choline (partial α7 agonist at ~10 mM; spirulina choline low; not direct α7 agonist at supplement doses; but sustained choline → neural ACh → α7 stimulation indirect).
AChE Oxidative Protection and Neuroinflammation
AChE oxidative inactivation: AChE Ser203 (catalytic; organophosphate/carbonyl target); AChE Met residues (Met311/Met537; 4-HNE lipid aldehyde modification → AChE activity ↓); H2O2/ONOO− → AChE Cys/Trp oxidation → AChE activity ↓ → synaptic ACh accumulation (double-edged: short-term → more ACh → receptor activation; long-term oxidative AChE loss → Alzheimer's/neurodegeneration); NF-κB → AChE upregulation (inflammation → NF-κB → ACHE promoter NF-κB sites → AChE expression ↑ → excess ACh hydrolysis → ACh ↓ → vagal anti-inflammatory reflex ↓ → positive feedback inflammation); spirulina: (1) NF-κB ↓ → ACHE promoter ↓ → neuroinflammatory AChE upregulation ↓ −20–30%; (2) Nrf2 → TRX/GSH → AChE Met311/537 oxidation ↓ → AChE structural integrity maintained; (3) Nrf2 → HO-1 CO → AChE haem-pocket (peripheral anionic site; CO modulation); net: synaptic ACh half-life +10–20% in neuroinflammatory context; vagal anti-inflammatory reflex capacity preserved.
mAChR M2/M4 Gq/Gi Downstream Modulation
mAChR M2 (Gi; cardiac; SA node M2 → I(KACh) → bradycardia; Gi → AC ↓ → cAMP ↓ → PKA ↓ → reduced Cav1.2 L-type → anti-chronotropic; also atrial K+ → hyperpolarisation); mAChR M3 (Gq; smooth muscle/exocrine; bronchial/gastrointestinal smooth muscle contraction; M3 → NO synthesis in endothelium (ACh → M3 endothelial → Gq → IP3 → Ca2+ → CaM → eNOS → NO → vasodilation (endothelium-dependent ACh relaxation)); M1 (Gq; CNS; cognitive; muscarinic Alzheimer's therapy target)): spirulina modulation: (1) eNOS: AMPK → eNOS Ser1177 → NO → vasodilation (parallels M3 endothelial pathway; additive or parallel NO-mediated vasodilation); (2) M2 cAMP: spirulina AMPK → PDE3A → cAMP ↓ (separate from M2-Gi→AC; both reduce cardiac PKA-Cav1.2 phosphorylation); (3) NF-κB ↓ → iNOS ↓ → ONOO− ↓ → M3 receptor Cys/Trp oxidative inactivation ↓ → endothelium-dependent ACh vasodilation maintained; (4) cognitive: AMPK → BDNF → M1 receptor sensitivity (neurotrophin-mAChR crosstalk); spirulina → cognitive ACh support (human: modest cognitive benefit 12 weeks; spirulina 5g + exercise).
Clinical Outcomes in Cholinergic Signalling
- TNF-α (α7-nAChR/NF-κB; LPS macrophage + spirulina): −20–35%
- Neuroinflammatory AChE (ACHE mRNA; NF-κB ↓; LPS model): −20–30%
- ACh-induced vasodilation (M3/eNOS/NO; aortic ring; spirulina pre-treatment): +15–25%
- Vagal tone (HRV; 12 weeks; spirulina supplementation): +5–15%
- Heart rate (M2-Gi/ACh; resting; spirulina 12 weeks; athletes): −2–4 bpm
- Cognitive function (MMSE-adjacent; 5g/day; 12 weeks + exercise): modest +
Dosing and Drug Interactions
Cholinergic/cognitive support: 5–10g daily with choline-rich diet (eggs/liver). AChE inhibitors (donepezil/rivastigmine; Alzheimer's): Spirulina ↓ neuroinflammatory AChE upregulation parallels AChE inhibitor mechanism; mechanistically complementary; no pharmacokinetic interaction; combined may reduce therapeutic AChE inhibitor dose requirement (theoretical; consult physician). Anticholinergics (atropine/oxybutynin/scopolamine): Spirulina ACh support potentially reduces anticholinergic efficacy slightly (increased ACh competes at mAChR); generally not clinically significant at supplement doses. α7-nAChR agonists (GTS-21/DMXBA; research/clinical trials): Spirulina anti-inflammatory convergent with α7 activation; additive NF-κB ↓; no pharmacokinetic concern. Organophosphates (pesticides; AChE inhibitors): Spirulina Nrf2 → AChE Met protection → partially reduces oxidative organophosphate-adjacent damage; does not counter irreversible Ser203 phosphorylation; not a medical antidote. Summary: TNF-α −20–35%, AChE (neuroinflam.) −20–30%, vasodilation +15–25%; dosing 5–10g. NK: low (AChE inhibitor complementary; anticholinergics minor interaction).